Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Shanghai Pharmaceuticals Commits $42M to SIIC Bio-Med Fund Targeting FIC/BIC Assets from IND to Phase II

Fineline Cube Jul 22, 2026
Company Deals

TYK Medicines and Qilu Pharmaceutical Forge Strategic Partnership for EGFR-TKI TY-9591 with $2.4B Deal

Fineline Cube Jul 22, 2026
Company Deals

Trinomab Biotechnology Debuts on Shanghai STAR Market with First-in-Class Anti-Tetanus Monoclonal Antibody

Fineline Cube Jul 22, 2026
Company Deals

Grand Pharma Partners with Siemens Healthineers to Commercialize AcuNav Lumos 4D ICE Catheter in China’s Structural Heart Market

Fineline Cube Jul 21, 2026
Company Deals Digital

Insilico Medicine Forms Quantum-AI Alliance with Byterna and DuneQ to Accelerate Next-Generation RNA and Peptide Therapeutics

Fineline Cube Jul 21, 2026
Policy / Regulatory

China Launches 12th Batch of National Drug Procurement with Vonoprazan and Vitamin B6 Drawing Record Competition

Fineline Cube Jul 21, 2026
Company Drug

Youcare Pharmaceutical Receives NMPA Approval for YKYY033 Clinical Trials Across Multiple Thrombotic Indications

Fineline Cube Jul 22, 2026
Company Drug

Junshi Biosciences Receives NMPA Acceptance for Toripalimab Expanded Indication in Resectable Stage II–III NSCLC

Fineline Cube Jul 22, 2026
Company Drug

Hengrui Pharmaceuticals Gains NMPA Approval for SHR-A1921 Clinical Study

Fineline Cube Feb 15, 2023

Jiangsu Hengrui Pharmaceuticals (SHA: 600276) has announced receiving the go-ahead from the National Medical Products...

Company Medical Device

Grand Pharma Completes First Atrial Fibrillation Treatment with HeartLight X3

Fineline Cube Feb 15, 2023

China-based Grand Pharmaceutical Group Limited (HKG: 0512) has announced the successful completion of the first...

Company Drug

Zelgen’s ZG2001 and ZG0895 Clinical Trials Approved by NMPA

Fineline Cube Feb 15, 2023

Suzhou Zelgen Biopharmaceuticals Co., Ltd (SHA: 688266) has announced that separate clinical trial filings for...

Company Drug

Innovent Biologics Initiates Phase II Study for IBI311 in Thyroid-Associated Ophthalmopathy

Fineline Cube Feb 15, 2023

China-based Innovent Biologics Inc., (HKG: 1801) has announced the first patient dosing in a Phase...

Company Deals

Hygea Medtech Secures Series D Funding for Oncology Device Expansion

Fineline Cube Feb 15, 2023

Hygea Medical Technology Co., Ltd, a leading minimally invasive device maker for oncology indications based...

Company Deals

CTI Acquires Vectoring Pharmatech to Expand Pharmacy CMC Research

Fineline Cube Feb 15, 2023

China-based Centre Testing International Group Co., Ltd (CTI), a leading third-party testing and qualification services...

Company Deals

Shenzhen United Family Hospital Partners with GBA Medical Delegation

Fineline Cube Feb 15, 2023

Shenzhen United Family Hospital has struck a partnership with a medical delegation from the Guangdong-Hong...

Company Deals

Vincentage Raises RMB 100 Million for Innovative Drug Development

Fineline Cube Feb 15, 2023

Suzhou-based new drug developer Vincentage has reportedly raised close to RMB 100 million (USD 14.6...

Company Deals

Sequanta and Grandomics Collaborate on Ultra-High Throughput Sequencing Lab

Fineline Cube Feb 15, 2023

Sequanta Technologies, a multi-omics research and clinical service provider based in Shanghai, and Grandomics Biosciences...

Company Deals

Luzhu Biotech Files for IPO in Hong Kong, Sponsored by CICC

Fineline Cube Feb 15, 2023

Beijing Luzhu Biotechnology Co., Ltd, a leading human vaccine and therapeutic biologics maker, has made...

Policy / Regulatory

China’s NRDL Update: New Drugs Available for Online Procurement

Fineline Cube Feb 15, 2023

Shanghai’s Sunshine Medical Procurement All-in-One (SMPA) drug procurement platform has released a notice stating that...

Company Medical Device

Mindray Launches First Wireless Handheld Ultrasound System, TE Air

Fineline Cube Feb 15, 2023

China-based medical device firm Mindray (SHE: 300760) has announced the market launch of the firm’s...

Company Deals

Harbour BioMed Licenses HBM7008 to Cullinan Oncology for US Development

Fineline Cube Feb 14, 2023

Harbour BioMed (HBM), which operates out of the Netherlands, the United States, and Suzhou, China,...

Company Drug

Kangtai Biological Begins Phase I Trial for Tetravalent Influenza Vaccine

Fineline Cube Feb 14, 2023

China-based Shenzhen Kangtai Biological Products Co., Ltd (SHE: 300601) has announced the first subject enrollment...

Company Drug

Jiangsu Recbio Completes First Tranche Enrollment for Shingles Vaccine REC610

Fineline Cube Feb 14, 2023

China-based Jiangsu Recbio Technology Co., Ltd has announced the completion of the first tranche of...

Company Drug

Beijing Wantai Initiates Phase I Study for 20-Valent Pneumonia Vaccine

Fineline Cube Feb 14, 2023

China-based Beijing Wantai Biological Pharmacy Enterprise Co., Ltd (SHA: 603392) has announced the initiation and...

Company Drug

Gracell Biotechnologies Gains IND Approval for GC012F in China

Fineline Cube Feb 14, 2023

Gracell Biotechnologies has reported receiving Investigational New Drug (IND) approval from the Center for Drug...

Hospital Policy / Regulatory

China’s Ministries Release Plan for Urban Medical Group Pilots

Fineline Cube Feb 14, 2023

A group of ministries led by the National Health Commission (NHC), including the National Development...

Company Deals Digital

ThinmedTech Partners with West China Hospital for CKD Digital Therapy

Fineline Cube Feb 14, 2023

ThinmedTech, a chronic disease clinical management solution provider based in Chongqing, has struck a partnership...

Company Drug

RemeGen Gains NMPA Approval for RC48 and Pyrotinib Clinical Study

Fineline Cube Feb 14, 2023

China-based RemeGen Ltd (HKG: 9995) has announced receiving the go-ahead from the National Medical Products...

Posts pagination

1 … 595 596 597 … 698

Recent updates

  • Shanghai Pharmaceuticals Commits $42M to SIIC Bio-Med Fund Targeting FIC/BIC Assets from IND to Phase II
  • TYK Medicines and Qilu Pharmaceutical Forge Strategic Partnership for EGFR-TKI TY-9591 with $2.4B Deal
  • Youcare Pharmaceutical Receives NMPA Approval for YKYY033 Clinical Trials Across Multiple Thrombotic Indications
  • Trinomab Biotechnology Debuts on Shanghai STAR Market with First-in-Class Anti-Tetanus Monoclonal Antibody
  • Novo Nordisk Sues Eli Lilly Over Alleged False Advertising of Zepbound and Mounjaro in GLP-1 Market
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Shanghai Pharmaceuticals Commits $42M to SIIC Bio-Med Fund Targeting FIC/BIC Assets from IND to Phase II

Company Deals

TYK Medicines and Qilu Pharmaceutical Forge Strategic Partnership for EGFR-TKI TY-9591 with $2.4B Deal

Company Drug

Youcare Pharmaceutical Receives NMPA Approval for YKYY033 Clinical Trials Across Multiple Thrombotic Indications

Company Deals

Trinomab Biotechnology Debuts on Shanghai STAR Market with First-in-Class Anti-Tetanus Monoclonal Antibody

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.